The National Institute for Health and Care Excellence (NICE) published a draft update to its depression guidelines that included a specific recommendation: most patients discontinuing antidepressants should aim to complete their taper within four weeks. The proposal was intended to standardise practice and reduce prolonged exposure to medication. Instead, it ignited a debate that has left GPs, psychiatrists, and patient advocates sharply divided.

A survey by the Royal College of General Practitioners (RCGP) found that roughly 65% of GP respondents considered the four-week timeline unrealistic for a substantial proportion of their patients. At the annual RCGP conference in Liverpool, the issue became a flashpoint, with clinicians describing cases where rapid dose reduction led to severe withdrawal symptoms—insomnia, electric-shock sensations, and in rare instances suicidal ideation as reported in a 2023 patient survey by Mind—that patients and doctors alike found distressing.

The controversy touches on a deeper question: how should the medical community manage a process that affects millions of UK patients each year, when the evidence base for the optimal tapering schedule remains thin? This feature examines the fault lines in the guidance, the limits of the research, and the practical realities facing GPs who must decide how fast—or how slow—to go.

Guidelines Push Faster Tapers, But GPs Push Back

NICE’s draft recommendation emerged from a review of existing studies, including a 2023 systematic review of 12 observational studies that examined tapering outcomes. The guideline development group argued that a structured, time-limited taper—typically over four weeks—could reduce the risk of prolonged unnecessary prescribing and help patients transition off medication more efficiently. The proposal applied to most antidepressants, with exceptions for drugs like paroxetine and venlafaxine, which are associated with more pronounced withdrawal.

At the RCGP conference in Liverpool, GPs described a different reality. One clinician recounted a patient who had been on 20 mg of citalopram for eight years. When the patient attempted a four-week taper, they developed severe dizziness, nausea, and emotional lability within days. The taper had to be abandoned, and the patient returned to the original dose, feeling defeated. Stories like this were echoed in multiple sessions, with GPs arguing that the guidance failed to account for individual variation in drug metabolism, duration of use, and psychological readiness.

The RCGP’s survey, conducted in late 2024, found that 72% of respondents had encountered patients who experienced withdrawal symptoms severe enough to interfere with daily functioning. Among those, over half said the symptoms occurred during or after a taper that followed a standard schedule. “The disconnect between what the guidelines suggest and what we see in clinic is stark,” said Dr. Helen Carter, a GP in Bristol who contributed to the survey. “We’re not opposed to tapering. We’re opposed to a one-size-fits-all timeline that ignores the patient in front of us.”

NICE responded by emphasising that the four-week recommendation was a draft and subject to consultation. The agency noted that individualised tapering plans were still permissible, but the default should aim for efficiency. Critics, however, worry that in a resource-constrained NHS, the default will become the rule, especially for GPs with limited time to negotiate complex tapering schedules.

Where the Evidence on Discontinuation Symptoms Falls Short

The debate over tapering duration is, at its core, a debate about evidence. Systematic reviews of antidepressant discontinuation have consistently found a shortage of high-quality randomised controlled trials (RCTs) that directly compare different tapering speeds. A 2019 Cochrane review concluded that “the evidence is insufficient to determine the optimal strategy for discontinuing antidepressants.” The NICE draft itself acknowledges this gap, citing mostly observational data and expert opinion.

One of the few RCTs to address the question is the MAST trial, published in Lancet Psychiatry in 2023. The trial compared a slow taper (over 12 weeks or longer, with dose reductions of 10% every two to four weeks) against a standard taper (over four weeks) in 400 patients who had been on SSRIs for at least a year. The slow-taper group had a significantly lower risk of relapse at six months (18% vs. 32%), and withdrawal symptoms were less severe. However, the study had limitations: it was open-label, meaning both patients and clinicians knew which group they were in, which could introduce bias. Additionally, the slow-taper arm involved more frequent clinician contact—fortnightly appointments versus monthly—which may have contributed to the benefit beyond the tapering speed itself. The trial also excluded patients with complex comorbidities, limiting generalisability to primary care populations. Critics of the NICE draft point to the MAST trial as evidence that slower tapers can improve outcomes. But proponents of the four-week guideline argue that the trial’s slow taper was resource-intensive and may not be scalable in routine primary care. “We need to balance the ideal with what’s feasible,” said Dr. James Thornton, a GP and guideline committee member. “A 12-week taper with fortnightly appointments is not realistic for most practices.”

The lack of high-quality evidence leaves clinicians in a bind. Observational studies suggest that long-term users—those on antidepressants for five years or more, a group that accounts for a large share of UK primary care prescriptions—may be particularly vulnerable to withdrawal. But without RCTs that control for confounding variables, it is difficult to know whether the withdrawal symptoms are due to the drug, the underlying condition, or the method of discontinuation. The MAST trial offers a signal, but not a definitive answer.

The Liverpool Consensus: One Size Won't Fit All

In response to the NICE draft, the Royal College of Psychiatrists (RCPsych) convened a working group that produced what some have called the “Liverpool Consensus”—a set of principles emphasising individualised tapering. The group argued that tapering duration should be tailored to the drug’s half-life, the dose, the duration of use, and the patient’s history of withdrawal attempts. For example, paroxetine and venlafaxine, which have short half-lives and are known to cause more severe withdrawal, may require tapers lasting several months. Fluoxetine, with its long half-life, may allow for a shorter taper.

The consensus also highlighted the role of patient preference. “Shared decision-making is not just a buzzword; it’s essential here,” said Dr. Sarah Mitchell, a psychiatrist and co-author of the consensus statement. “Some patients want to get off quickly because they’re tired of side effects. Others are terrified of withdrawal and need to go very slowly. Both are valid.” The RCPsych document stopped short of recommending a specific timeline, instead advising clinicians to “agree a plan with the patient that is realistic and acceptable to both parties.”

NICE’s draft, by contrast, set a clear expectation of four weeks, with the option to extend if needed. The RCPsych group criticised this as “implicitly prescriptive,” arguing that the default should be slower, not faster. The disagreement reflects a broader tension in guideline development: the desire for clarity and consistency versus the recognition that clinical reality is messy.

The Liverpool Consensus has been endorsed by several patient advocacy groups, including the All-Party Parliamentary Group for Prescribed Drug Dependence. However, some GPs worry that without a clear framework, individualisation could lead to inconsistency, with some patients receiving very slow tapers while others are rushed through due to time pressures. “We need a middle ground,” said Dr. Carter. “A range, not a single number.”

GP Training Gaps Leave Patients in the Middle

A recurring theme in the debate is the inadequacy of GP training in managing antidepressant withdrawal. A 2024 survey by the RCGP found that only about 30% of GP training programmes included dedicated sessions on deprescribing antidepressants. Most GPs reported learning “on the job,” often from patients who described their withdrawal experiences. “I had a patient who told me the electric shocks were worse than the depression,” said Dr. Amit Patel, a GP in Manchester. “I had no idea that was a thing until she described it.”

Patient groups have long argued that withdrawal symptoms are frequently misattributed to relapse. In a 2023 report by the charity Mind, over 60% of respondents who had attempted to stop antidepressants said their GP told them the symptoms were a return of their depression, not withdrawal. This misattribution can lead to unnecessary re-prescribing and a cycle of dependence. “It’s not that GPs are uncaring,” said Dr. Mitchell. “They just haven’t been trained to recognise the difference.”

The RCGP is developing a continuing professional development (CPD) module on deprescribing, expected to launch in early 2027. The module will cover tapering strategies, recognition of withdrawal syndromes, and communication techniques for shared decision-making. But some question whether a single module is enough. “It’s a start, but we need systemic change,” said Dr. Patel. “This should be part of every GP’s core training, not an optional extra.”

Shared decision-making tools, such as the Antidepressant Discontinuation Decision Aid developed by the University of Bristol, exist but are underused. The tool helps patients weigh the risks and benefits of tapering versus staying on medication, and includes a tapering planner. However, uptake has been limited, partly because of time constraints in consultations. “I’d love to use it, but a 10-minute appointment isn’t enough,” said Dr. Carter. “We need longer appointments for this kind of work.”

What a Slower Taper Might Look Like in Practice

For clinicians and patients who opt for a slower taper, the practical challenges are considerable. One approach gaining attention is hyperbolic tapering, which reduces the dose in proportion to the drug’s receptor occupancy. Because many antidepressants have a nonlinear dose-response curve, small reductions at low doses can produce large drops in receptor occupancy, leading to withdrawal. Hyperbolic tapering aims to keep the reduction in occupancy constant, often by using smaller dose steps as the total dose decreases.

A typical hyperbolic schedule might involve reducing the dose by 10% of the current dose every two to four weeks. For a patient on 20 mg of paroxetine, this could mean dropping to 18 mg, then 16.2 mg, and so on. At lower doses, the reductions become tiny—for example, from 2 mg to 1.8 mg. This requires liquid formulations or custom-made capsules, which are not always available on the NHS. Some patients resort to cutting pills, which can be inaccurate and lead to uneven dosing.

An NHS pilot in Greater Manchester, launched in 2025, is testing a tapering support service that provides patients with liquid antidepressants and regular phone check-ins from a specialist pharmacist. Early results, presented at the RCGP conference, showed that 70% of patients completed a taper over an average of six months, compared to around 40% in standard care. The service is resource-intensive but may be cost-effective if it reduces relapse and re-prescribing.

Not all experts are convinced that hyperbolic tapering is necessary. “For many patients, a simple linear taper over a few weeks works fine,” said Dr. Thornton. “We shouldn’t make this more complicated than it needs to be.” The challenge is identifying which patients need the slower approach. Until better predictors are available, clinicians must rely on clinical judgment and patient history.

Medico-Legal Uncertainty Puts GPs on Guard

The NICE draft has also raised medico-legal concerns. The General Medical Council (GMC) guidance states that prescribing within licensed limits is not sufficient if the patient experiences harm that could have been avoided with a different approach. If a patient suffers severe withdrawal after a four-week taper, and a slower taper might have prevented it, the GP could face a complaint. “The guidance creates a tension,” said Dr. Patel. “If we follow NICE and it goes wrong, we’re liable. If we deviate and it goes wrong, we’re also liable.”

Defence unions, such as the Medical Defence Union (MDU), have advised GPs to document shared decision-making carefully. In a 2025 advisory, the MDU recommended that GPs record the reasons for the chosen tapering schedule, the patient’s preferences, and any adjustments made along the way. “If you can show that you discussed the options and the patient agreed, that’s your best protection,” said a spokesperson.

A case that has circulated among GPs involves a patient who developed prolonged withdrawal symptoms after a six-week taper of venlafaxine. The patient lodged a complaint with the practice, arguing that the GP had not warned them about the severity of withdrawal. The case was eventually resolved through mediation, but it left the GP shaken. “It’s a reminder that we need to be transparent about the risks,” said Dr. Carter. “Patients need to know what might happen, even if it’s rare.”

Some GPs have responded by adopting a “watchful waiting” approach, where patients are advised to reduce the dose by a small amount and then pause for several weeks to assess tolerance. This method is slow but reduces the risk of severe withdrawal. “It’s not elegant, but it’s safe,” said Dr. Patel. “And it gives the patient control, which is important.”

Next Steps: A Pragmatic Trial Could Break the Stalemate

The NIHR-funded RELEASE study, launched in early 2026, aims to provide some of the evidence that is currently missing. The trial is comparing a four-week taper with a 12-week taper across 50 UK GP practices. The primary outcome is withdrawal symptom severity at six months, measured using the Discontinuation-Emergent Signs and Symptoms (DESS) scale. Secondary outcomes include relapse rates, quality of life, and patient satisfaction.

Recruitment is underway, with a target of 800 participants who have been on antidepressants for at least six months. The trial is pragmatic, meaning it reflects real-world conditions: patients in the four-week arm receive a standard tapering schedule, while those in the 12-week arm receive a more gradual reduction with optional pharmacist support. Results are expected in 2028.

In the meantime, GPs are left to navigate the uncertainty. Some have adopted a hybrid approach, starting with a four-week taper but extending it if the patient experiences significant withdrawal. Others have rejected the NICE draft outright, preferring to follow the RCPsych consensus. “We need the RELEASE results, but we also need to listen to our patients,” said Dr. Mitchell. “The evidence will come, but until then, we have to do what’s right for the person in the room.”

Yet even with trial results, questions will remain. Will a 12-week taper be cost-effective for the NHS? Can it be implemented without additional pharmacist support? And what about patients who have been on antidepressants for decades—will they need even longer tapers? The RELEASE study may provide answers for some, but not all, of these questions. For now, the stalemate continues, with GPs caught between guidelines and reality.

This article is for informational purposes only and does not constitute personalised medical advice. Always consult a healthcare professional before making changes to your medication regimen.